Modification of a Selective NTRK2 Agonist and Confirmation of Activity in a Glaucoma-on-a-Chip Model
Abstract Purpose: RNYK is a selective agonist of the neurotrophic tyrosine kinase receptor type 2 (NTRK2) which has been screened from a phage-displayed peptide library. Its sequence is SGVYKVAYDWQH, similar to a native NTRK2 ligand, that is, brain-derived neurotrophic factor (BDNF). The current stu...
Main Authors: | Fatemeh Nafian, Shahin Yazdani, Mohammad Javad Rasaee, Babak Kamali Doust Azad, Narsis Daftarian, Mozhgan Rezaei Kanavi |
---|---|
Format: | Article |
Language: | English |
Published: |
Knowledge E
2024-03-01
|
Series: | Journal of Ophthalmic & Vision Research |
Subjects: | |
Online Access: | https://doi.org/10.18502/jovr.v19i1.15439 |
Similar Items
-
A lab‐on‐a‐chip model of glaucoma
by: Fatemeh Nafian, et al.
Published: (2020-10-01) -
NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern
by: Vanessa Young, et al.
Published: (2022-06-01) -
Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma
by: Jeffrey L. Goldberg, MD, PhD, et al.
Published: (2023-09-01) -
Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair
by: Adam Rivnyak, et al.
Published: (2018-03-01) -
Synergistic neurotrophic effects of piracetam and thiotriazoline
by: O. A. Gromova, et al.
Published: (2016-03-01)